Kim Sang-Hee, Byun Youngsoon
Author Affiliations: College of Nursing, Keimyung University, Dalgubuldaero, Dalseo-gu, Daegu (Dr Kim); and Division of Nursing Science, College of Health Science, Ewha Womans University, Daehyun-Dong, Seodaemun-Gu (Dr Byun), Seoul, Korea.
Cancer Nurs. 2018 Jan/Feb;41(1):E38-E47. doi: 10.1097/NCC.0000000000000435.
Symptom clusters must be identified in patients with high-grade brain cancers for effective symptom management during cancer-related therapy.
The aims of this study were to identify symptom clusters in patients with high-grade brain cancers and to determine the relationship of each cluster with the performance status and quality of life (QOL) during concurrent chemoradiotherapy (CCRT).
Symptoms were assessed using the Memorial Symptom Assessment Scale, and the performance status was evaluated using the Karnofsky Performance Scale. Quality of life was assessed using the Functional Assessment of Cancer Therapy-General. This prospective longitudinal survey was conducted before CCRT and at 2 to 3 weeks and 4 to 6 weeks after the initiation of CCRT.
A total of 51 patients with newly diagnosed primary malignant brain cancer were included. Six symptom clusters were identified, and 2 symptom clusters were present at each time point (ie, "negative emotion" and "neurocognitive" clusters before CCRT, "negative emotion and decreased vitality" and "gastrointestinal and decreased sensory" clusters at 2-3 weeks, and "body image and decreased vitality" and "gastrointestinal" clusters at 4-6 weeks). The symptom clusters at each time point demonstrated a significant relationship with the performance status or QOL.
Differences were observed in symptom clusters in patients with high-grade brain cancers during CCRT. In addition, the symptom clusters were correlated with the performance status and QOL of patients, and these effects could change during CCRT.
The results of this study will provide suggestions for interventions to treat or prevent symptom clusters in patients with high-grade brain cancer during CCRT.
对于高级别脑癌患者,必须识别症状群,以便在癌症相关治疗期间进行有效的症状管理。
本研究的目的是识别高级别脑癌患者的症状群,并确定每个症状群与同步放化疗(CCRT)期间患者的功能状态和生活质量(QOL)之间的关系。
使用 Memorial 症状评估量表评估症状,使用 Karnofsky 功能状态量表评估功能状态。使用癌症治疗功能评估通用量表评估生活质量。这项前瞻性纵向调查在 CCRT 前以及 CCRT 开始后的 2 至 3 周和 4 至 6 周进行。
共纳入 51 例新诊断的原发性恶性脑癌患者。识别出六个症状群,每个时间点出现两个症状群(即 CCRT 前的“负面情绪”和“神经认知”群,2 - 3 周时的“负面情绪和活力下降”以及“胃肠道和感觉减退”群,4 - 6 周时的“身体形象和活力下降”以及“胃肠道”群)。每个时间点的症状群与功能状态或生活质量均呈现显著关系。
在 CCRT 期间,高级别脑癌患者的症状群存在差异。此外,症状群与患者的功能状态和生活质量相关,且这些影响在 CCRT 期间可能会发生变化。
本研究结果将为在 CCRT 期间治疗或预防高级别脑癌患者症状群的干预措施提供建议。